Most (26/29, 90%) AITL patients had CD30 expression between 10% and 30%; CD30 expression among patients with PTCL-NOS was more widely distributed from 10% to 100% (Supplementary Figure S2A, available at https://doi.org/10.1016/j.annonc.2021.12.002). This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.